Apollon Wealth Management LLC acquired a new stake in shares of Balchem Co. (NASDAQ:BCPC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,087 shares of the basic materials company's stock, valued at approximately $503,000.
A number of other large investors also recently bought and sold shares of the business. Inspire Investing LLC raised its stake in Balchem by 2.7% in the third quarter. Inspire Investing LLC now owns 2,348 shares of the basic materials company's stock worth $413,000 after buying an additional 62 shares in the last quarter. Heritage Family Offices LLP raised its stake in Balchem by 8.3% in the fourth quarter. Heritage Family Offices LLP now owns 1,420 shares of the basic materials company's stock worth $231,000 after buying an additional 109 shares in the last quarter. Westside Investment Management Inc. bought a new position in Balchem in the third quarter worth approximately $27,000. SageView Advisory Group LLC raised its stake in Balchem by 3.8% in the third quarter. SageView Advisory Group LLC now owns 4,653 shares of the basic materials company's stock worth $819,000 after buying an additional 169 shares in the last quarter. Finally, Portside Wealth Group LLC increased its position in shares of Balchem by 12.5% during the third quarter. Portside Wealth Group LLC now owns 1,551 shares of the basic materials company's stock worth $273,000 after purchasing an additional 172 shares in the last quarter. Institutional investors own 87.91% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on BCPC. StockNews.com raised Balchem from a "hold" rating to a "buy" rating in a research report on Monday, October 28th. HC Wainwright upped their price target on Balchem from $185.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, November 4th.
Check Out Our Latest Analysis on BCPC
Balchem Stock Up 1.0 %
Shares of BCPC stock traded up $1.68 during trading hours on Monday, reaching $164.82. 131,072 shares of the company's stock were exchanged, compared to its average volume of 114,008. The stock's 50 day moving average is $163.23 and its 200-day moving average is $169.45. The company has a market cap of $5.36 billion, a price-to-earnings ratio of 44.31, a P/E/G ratio of 4.42 and a beta of 0.69. The company has a current ratio of 2.98, a quick ratio of 1.90 and a debt-to-equity ratio of 0.21. Balchem Co. has a fifty-two week low of $137.69 and a fifty-two week high of $186.03.
Balchem Increases Dividend
The business also recently disclosed an annual dividend, which was paid on Friday, January 17th. Stockholders of record on Thursday, December 26th were issued a dividend of $0.87 per share. The ex-dividend date of this dividend was Thursday, December 26th. This is a positive change from Balchem's previous annual dividend of $0.79. This represents a dividend yield of 0.4%. Balchem's payout ratio is 23.39%.
Balchem Company Profile
(
Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
See Also

Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.